A MORE accurate and earlier test that will help save the lives of colorectal cancer sufferers will be developed in a $763,000 Brumby Labor Government pilot research project.
23/07/2009
AUSTRALIAN cancer experts have agreed women should not undergo testing for ovarian cancer unless they are experiencing signs or symptoms of the disease.
06/10/2009
SPECTRUM Pharmaceuticals has announced the FDA has granted Fast Track Designation for the investigation of apaziquone (EOquin) for the treatment of non-muscle invasive bladder cancer.
24/07/2009
The number of pancreatic cancer cases in New South Wales had nearly doubled for males and tripled for females in the last 30 years.
18/03/2010
A REPORT on the National Bowel Cancer Screening Program (NBCSP) has shown the program is working to save lives.
06/10/2009
Roche has announced the results of a phase III trial investigating the use of Avastin (bevacizumab) in combination with docetaxel chemotherapy and prednisone in men with late stage prostate cancer (hormone-refractory / HRPC). The study, known as CALGB 90401, did not meet its primary objective of extending overall survival compared to chemotherapy and prednisone alone.
18/03/2010
Merck has begun a Phase III study of the therapeutic cancer vaccine Stimuvax (BLP25 liposome vaccine) in Asian patients with advanced non-small cell lung cancer (NSCLC). The study will investigate if Stimuvax can extend overall survival in Asian patients with unresectable stage III NSCLC.
14/12/2009
RESEARCHERS at the University of Toronto have created a device no bigger than a Blackberry which is able to analyse and detect cancer biomarkers using only minute quantities of biological samples.
02/10/2009
Researchers conducting a phase 1 clinical trial are investigating whether a vaccine can be used to treat progressive stage D0 prostate cancer.
30/03/2010
SCIENTISTS say that they have perfected a therapy to destroy drug-resistant tumour cells.
30/06/2009
bioMérieux has signed an agreement with GlaxoSmithKline to develop a predictive test to help clinicians select the most appropriate treatment for breast cancer patients.
18/11/2009
AUSTRALIAN researchers at the CSIRO Preventative Health National Research into Colorectal Cancer and Gut Health, Flinders University and Clinical Genomics have developed gene expression biomarkers which can accurately discriminate pre-cancerous and cancerous colorectal growths from non-cancerous controls.
04/06/2009
Women with breast cancer who have inherited mutations in the BRCA1 or BRCA2 genes are more likely to develop breast cancer later in life in the opposite (contralateral) breast. German researchers have estimated the risk of contralateral breast cancer is related to the woman’s age when she was first diagnosed and whether she has inherited a mutation in either BRCA1 or BRCA2 genes.
05/11/2009
Prima BioMed has engaged the Unversity of New South Wales (UNSW) and University of Queensland (UQ) to undertake research into developing an oral delivery system for vaccines for cervical cancer.
20/11/2009
Australian researchers are members of an international consortium entering a new era of personalised medicine for cancer patients.
03/05/2010
PRIMA Biomed has secured $12m in funding to advance the commercialisation of the CVac ovarian cancer vaccine treatment product.
17/03/2009
Overdiagnosis of invasive breast cancer in NSW could be as high as 29% say University of Sydney researchers, suggesting that some women undergo unnecessary treatment.
17/11/2009
A STUDY released by the Translational Genomics Research Institute (TGen) has claimed cancer patients are able to survive longer under treatments based on their individual genetic profiles.
21/04/2009
A RESEARCHER from Purdue University has developed probes which can help pinpoint the location of tumours and might one day be able to directly attack cancer cells.
18/03/2009
FURTHER to its work with the University of Pittsburgh, PGxHealth has announced its research collaboration with the Dana-Farber Cancer Institute (DCFI) to validate the use of genetic variants in Fc gamma receptors (FCGRs), in predicting response to trastuzumab (Herceptin) therapy in patients with breast cancer.
21/05/2009